Skip to main content

Table 2 Details of the chemotherapy regimens and number of cycles between patients with and without LS

From: Incidence and predictors of Lhermitte’s sign among patients receiving mediastinal radiation for lymphoma

Chemotherapy No LS LS
2–4 ABVD/AVD 24 9
>4 ABVD/AVD 22 11
≥6 R-CHOP 2 1
≥6 R-EPOCH 6 2
≥6 HyperCVAD 1 0
Salvage 20 7
  1. ABVD/AVD: Doxorubicin, Bleomycin, Vinblastine, Dacarbazine
  2. R-CHOP: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
  3. R-EPOCH: Rituximab, Etoposide, Prednisolone, Vincristin, Cyclophosphamide, Doxorubicin
  4. HyperCVAD: Cyclophosphamide, Vincristine, Doxorubicin, Dexamethasone, Methotrexate, Cytarabine
  5. Salvage: Multiple lines of chemotherapy +/− Stem cell transplantation